Zealand Pharma A/S (OTCMKTS:ZLDPF – Get Free Report) will likely be posting its results before the market opens on Thursday, November 12th. Analysts expect the company to announce earnings of ($1.5714) per share and revenue of $1.33 million for the quarter.
Zealand Pharma A/S Trading Up 6.5%
Shares of OTCMKTS:ZLDPF opened at $36.85 on Tuesday. The company’s 50-day moving average price is $39.26 and its two-hundred day moving average price is $47.12. Zealand Pharma A/S has a one year low of $33.08 and a one year high of $83.12. The company has a debt-to-equity ratio of 0.02, a current ratio of 13.98 and a quick ratio of 13.98. The stock has a market capitalization of $2.64 billion, a PE ratio of 5.74 and a beta of 0.99.
Wall Street Analyst Weigh In
A number of analysts recently issued reports on ZLDPF shares. Barclays downgraded Zealand Pharma A/S from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, September 8th. Jefferies Financial Group cut Zealand Pharma A/S from a “strong-buy” rating to a “hold” rating in a research report on Monday, July 13th. Zacks Research upgraded Zealand Pharma A/S from a “hold” rating to a “strong-buy” rating in a research note on Monday, October 12th. Finally, Wells Fargo & Company restated an “overweight” rating on shares of Zealand Pharma A/S in a research note on Thursday, August 13th. Two analysts have rated the stock with a Strong Buy rating, one has issued a Buy rating and eight have issued a Hold rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Hold”.
Check Out Our Latest Stock Report on Zealand Pharma A/S
About Zealand Pharma A/S
Zealand Pharma A/S is a biotechnology company headquartered in Copenhagen, Denmark. Founded in 1998, it discovers and develops peptide-based medicines, with a focus on metabolic diseases and rare conditions.
The company’s portfolio has included Zegalogue (dasiglucagon), an injectable treatment approved in the United States for severe hypoglycemia in people with diabetes. Zealand also develops investigational medicines for areas such as obesity, liver disease and rare gastrointestinal disorders, and works with pharmaceutical partners to advance and commercialize selected programs.
Zealand Pharma serves international markets through its development and commercial partnerships.
Read More
- Five stocks we like better than Zealand Pharma A/S
- Wall Street May Be Making a Big Mistake With monday.com Stock
- Are These 2 Mid-Cap Growth Stocks Worth the Risk?
- Oklo Changes the Narrative: Does a Nuclear Stock Price Explosion Come Next?
- Cloudflare’s 20% Sell-Off May Have Created an Opening for Investors
Receive News & Ratings for Zealand Pharma A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zealand Pharma A/S and related companies with MarketBeat.com's FREE daily email newsletter.
